Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism

Tracking to Announce Top line data in Q1 2022 REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing...
September 07, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
August 10, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME

REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases...
August 03, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
June 28, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Added to Russell Microcap® Index

REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related...
May 27, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute to Participate in Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases related to...
May 20, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs

REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
May 18, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose...
May 17, 2021 16:05 ET | Source: Rezolute, Inc.

Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated...
May 17, 2021 07:00 ET | Source: Rezolute, Inc.

Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit

REDWOOD CITY, Calif., May 17, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right